Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for PGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -1.316M
March 31, 2026 -0.255M
December 31, 2025 -0.14M
September 30, 2025 -0.839M
June 30, 2025 0.464M
March 31, 2025 0.205M
December 31, 2024 -78.40M
September 30, 2024 -32.13M
June 30, 2024 -0.052M
March 31, 2024 0.00
December 31, 2023 0.00
September 30, 2023 0.00
June 30, 2023 0.693M
March 31, 2023 -73.50M
December 31, 2022 0.00
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 -0.001M
December 31, 2021 -0.005M
September 30, 2021 -0.351M
June 30, 2021 -0.141M
March 31, 2021 -121.16M
December 31, 2020 -0.048M
September 30, 2020 -0.003M
June 30, 2020 -0.066M
Date Value
March 31, 2020 -35.00M
December 31, 2019 0.00
September 30, 2019 -0.006M
June 30, 2019 0.00
March 31, 2019 -6.918M
December 31, 2018 -1.262M
September 30, 2018 -0.178M
June 30, 2018 -0.572M
March 31, 2018 -88.31M
December 31, 2017 -13.80M
September 30, 2017 -0.189M
June 30, 2017 -0.503M
March 31, 2017 -0.165M
December 31, 2016 -0.985M
September 30, 2016 -0.509M
June 30, 2016 -7.894M
March 31, 2016 -9.777M
December 31, 2015 -2.254M
September 30, 2015 -220.02M
June 30, 2015 -7.815M
March 31, 2015 -112.61M
December 31, 2014 -0.215M
September 30, 2014 -0.298M
June 30, 2014 -0.646M
March 31, 2014 -25.07M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Geron Corp. -1.384M
Neurocrine Biosciences, Inc. -128.50M
Elicio Therapeutics, Inc. -16.51M
Agenus, Inc. -14.71M
Amgen, Inc. 0.00